Sequist, Lecia VLecia VSequistCHIH-HSIN YANGYamamoto, NobuyukiNobuyukiYamamotoO'Byrne, KennethKennethO'ByrneHirsh, VeraVeraHirshMok, TonyTonyMokGeater, Sarayut LucienSarayut LucienGeaterOrlov, SergeySergeyOrlovTsai, Chun-MingChun-MingTsaiBoyer, MichaelMichaelBoyerSu, Wu-ChouWu-ChouSuBennouna, JaafarJaafarBennounaKato, TerufumiTerufumiKatoGorbunova, VeraVeraGorbunovaLee, Ki HyeongKi HyeongLeeShah, RiyazRiyazShahMassey, DanDanMasseyZazulina, VictoriaVictoriaZazulinaShahidi, MehdiMehdiShahidiSchuler, MartinMartinSchuler2023-08-212023-08-212023-06-010732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/634650The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).en[SDGs]SDG310.1200/JCO.22.02547372359762-s2.0-85160372711https://api.elsevier.com/content/abstract/scopus_id/85160372711